Moderna Q2 Earnings Review: Downsizing Triggers Selloff, But I'm Long-Term Bullish

Moderna reported significant Q2 2025 losses, with net income of $(0.8bn) on just $0.1bn revenue, a sharp decline from its pandemic-era performance, prompting a 10% workforce reduction and a strategic focus on cost-cutting to achieve $4.7-$5bn in reductions by 2027. Despite these financial headwinds and an expected full-year 2025 loss of around $4.5bn, the company highlighted promising Phase 3 data for its seasonal flu vaccine (mRNA-1010), demonstrating 26.6% higher efficacy than comparators, and continued progress in its oncology collaboration with Merck. This pivot towards pipeline execution and financial discipline, alongside recent product approvals for RSV and mNEXSPIKE, underpins the analyst's reiterated 'Buy' rating, viewing the recent stock sell-off as a potential contrarian buying opportunity given the long-term potential of its mRNA platform.

Analysis

Moderna's Q2 2025 financial results starkly illustrate its post-pandemic transition, with revenues collapsing to $0.1 billion and a net loss of $(0.8) billion, a dramatic reversal from the $4.7 billion revenue and $5.2 billion net income reported in Q2 2022. This performance, contributing to a projected full-year 2025 loss of approximately $4.5 billion, has necessitated significant operational restructuring, including a 10% headcount reduction and an aggressive cost-cutting plan targeting $4.7-$5 billion in expenses by 2027. Despite the severe stock price decline of over 70% in the past year, the investment thesis is shifting from historical earnings to future pipeline potential. Key near-term catalysts include the company's seasonal flu vaccine, mRNA-1010, which demonstrated 26.6% higher efficacy than a licensed comparator in a 40,000-person study, positioning it for a potential Biologics License Application. Furthermore, progress continues on the high-potential intismeran oncology vaccine in collaboration with Merck, with multiple late-stage trials underway, although readouts remain 1-2 years out and are event-driven. The company is navigating a challenging environment marked by intense cash burn, a competitive RSV market, and potential regulatory hurdles, but its focus on rationalizing its pipeline and managing costs represents a critical pivot toward long-term sustainability.

Key Decisions for Investors

• Investors with a higher risk tolerance could consider the sharp, post-earnings stock decline as a potential contrarian entry point, based on the long-term potential of the company's mRNA pipeline and recent cost-cutting measures.
• Closely monitor the regulatory pathway and eventual submission of the Biologics License Application for the seasonal flu vaccine, mRNA-1010, as its approval represents the most significant near-term catalyst for revenue generation and valuation upside.
• Track the company's quarterly cash burn and progress towards its stated cost-reduction goals, as failure to stabilize its financial position could jeopardize its ability to fund its late-stage pipeline to completion.
• Factor in the binary risk associated with the intismeran oncology program, as positive data within the next two years could dramatically rerate the stock, while any setbacks or perceived lack of commitment from partner Merck could apply further pressure.